DERINAT (The solution for the / m)

Active material: deoxyribonucleat sodium
When ATH: L03A
CCF: Immunomodulator
ICD-10 codes (testimony): A15, A40, A41, A56.0, A56.1, B96.0, D25, i20, I73.0, I73.1, I73.9, I79.2, I83.2, J44, K12, K25, K26, K29, M05, N40, N41, N70, N71, N80, T30, Z51.8
When CSF: 14.01.09
Manufacturer: TEHNOMEDSERVIS ZAO FP {Russia}

Pharmaceutical form, composition and packaging

The solution for the / m clear, colorless, without foreign impurities.

Excipients: sodium chloride (0.9 g), water d / and (to 100 ml).

2 ml – glass bottles (10) – pallets (1) – packs cardboard.

The solution for the / m clear, colorless, without foreign impurities.

Excipients: sodium chloride (0.9 g), water d / and (to 100 ml).

5 ml – glass bottles (5) – pallets (1) – packs cardboard.

Pharmacological action

Immunomodulator, affects cellular and humoral immunity. Immunomodulatory effect Derinat^® caused by stimulation of B-lymphocytes, activation of T-helper cells. Derinat^® It activates the body's non-specific resistance, optimizing the inflammatory reaction and immune response to the bacterial, viral and fungal antigens. Derinat^® It stimulates reparative and regenerative processes.

Increases resistant to infection. Adjusts hematopoiesis (normalizing the number of leukocytes, lymphocytes, granulocytes, fagotsitov, Platelet). Having expressed lymphotropic, Derinat^® It stimulates drainage detoxification function of the lymphatic system. Derinat^® significantly reduces the sensitivity of cells to the damaging effects of chemotherapeutic drugs and radiotherapy.

Pharmacokinetics

Absorption and distribution

Rapidly absorbed from the injection site when the / m introduction and lymphatic spread to organs and tissues. Deoxyribonucleat sodium has a high affinity for bodies of hematopoiesis, It has been actively involved in cellular metabolism, embedding into cell structures. Maximally accumulated in the bone marrow, lymph nodes, Thymus, spleen, less – liver, brain, stomach, small and large intestine.

In the phase of intensive preparation revenue into the blood redistribution between plasma and formed elements of blood, in parallel with the metabolism and excretion. After a single injection for all concentration-time curve, describing the change in drug concentration in the investigated organs and tissues, characterized by rapid phase increase and decrease the concentration of fast phase in the range of 5-24 no. After the / m of C_max achieved through 5 no. The drug crosses the blood-brain barrier. C_max drug in the brain is achieved by 30 m.

Metabolism and excretion

Deoxyribonucleat sodium is metabolized in the body. Write mainly kidneys and partially with faeces. T_1/2 when i / m administration is 72.3 no.

Testimony

- Radiation damage;

- A violation of hematopoiesis;

- Mielodeprescia and resistance to cytostatics in cancer patients, develop on the background of cytostatic and / or radiation therapy (stabilization of hematopoiesis, reduction of cardio- and myelotoxicity of chemotherapeutic agents);

- Stomatitis, induced by cytostatic therapy;

- Gastric ulcer and duodenal ulcer, erosive gastro;

- CHD;

- Obliterating vascular diseases of the lower extremities stage II-III;

- Sores, nonhealing wounds;

- Odontohennыy sepsis, pyo-septic complications;

- Rheumatoid arthritis;

- Burn disease;

- Preoperative and postoperative periods (in surgical practice);

- Chlamydia, ureaplazmoz, Mikoplasmosis;

- Endometritis, salpingo-oophoritis, endometriosis, fibroids;

- Prostatitis, benign prostatic hyperplasia;

- Chronic obstructive pulmonary disease;

- Pulmonary tuberculosis, inflammatory diseases of the respiratory tract.

Dosage regimen

Derinat^® appointed adult / m (techenie1-2 in minutes) in an average single dose of 75 mg (5 ml solution for i / m administration 15 mg / ml) intervals administration 24-72 no.

At CHD appoint / m 5 ml 15 mg / mL in 48-72 no, a course of treatment – 10 injection.

At gastric ulcer and duodenal ulcer appoint / m 5 ml 15 mg / mL in 48 no, a course of treatment – 5 injection.

At oncological diseases – / m 5 ml (75 mg / day) through 24-72 no, a course of treatment – 10 injection.

IN Gynecology (endometritis, Chlamydia, ureaplazmoz, Mikoplasmosis, salpingo-oophoritis, fibroids, endometriosis) – / m 5 ml 15 mg / mL in 24-48 no, a course of treatment – 10 injection.

IN andrologii (prostatitis, benign prostatic hyperplasia) – / m 5 ml 15 mg / mL in 24-48 no, a course of treatment – 10 injection.

At tuberculosis – / m 5 ml 15 mg / mL in 24-48 no, a course of treatment – 10-15 injection.

At acute inflammatory diseases – / m 5 ml 15 mg / mL in 24-72 no, a course of treatment – 3-5 injection.

At chronic inflammatory diseases – / m 5 ml 15 mg / ml: first 5 injections at intervals 24 h each, subsequent – Each intervals 72 no, the general course of treatment – 10 injection.

When using the solution 15 mg / ml 2 ml / m administered daily injections, Doing recalculated, until the course dose 375-750 mg.

In children multiplicity / m administration is the same, in adults. Children under 2 years drug administered in an average single dose 7.5 mg (0.5 ml solution for i / m administration 15 mg / ml), in children aged 2 to 10 years single dose is determined by calculating 0.5 ml per year of life. In childrenolder 10 years The average single dose is 75 mg (5 ml solution for i / m administration 15 mg / ml), kursovaya dose – to 5 injections.

Side effect

Maybe: in patients with diabetes is marked hypoglycemic effect, which should be taken into account, controlling the blood glucose level.

Contraindications

- Hypersensitivity to the drug.

Pregnancy and lactation

The patient should be warned, that before the application of the drug during pregnancy and lactation is necessary to consult a doctor. The appointment of the drug during pregnancy should estimate the expected benefit to the mother and the potential risk to the fetus.

Cautions

The drug has no embryotoxic, teratogenic and carcinogenic.

Perhaps s / c administration of the drug.

The drug potentiates the therapeutic effect of basic therapy for stomach ulcers and duodenal ulcers.

Derinat^® reduce iatrogenic basic drugs for the treatment of rheumatoid arthritis with achievement 50% and 70% improvement on a number of integrated indicators of disease activity.

Surgical sepsis introduction Derinat^® in the complex therapy causes a decrease in the level of intoxication, activation of immunity, normalization of hematopoiesis, improves the functioning of organs, responsible for detoxification processes of the internal environment (incl. lymph nodes, spleen).

According to recent clinical studies have proven the effectiveness of Derinat in patients with acute exacerbation of COPD of varying severity with standard therapy. Assign / m 5 ml 15 mg / mL in 24-48 no, a course of treatment – 5-10 injection.

Overdose

Overdose symptoms are not observed.

Drug Interactions

Application Derinat^® in complex therapy improves the efficiency and reduce the duration of therapy, with a substantial reduction of doses of antibiotics and antiviral agents, with increasing periods of remission.

Derinat^® It increases the effectiveness of antitumor antibiotics anthracyclines, cytostatics.

Conditions of supply of pharmacies

The drug is released under the prescription.

Conditions and terms

The drug should be stored out of reach of children, dry, dark place at a temperature of 4 ° to 20 ° C. Shelf life - 5 years.